10-Q: Venus Concept Inc. Reports Q3 2024 Results Amid Strategic Review

Venus Concept Inc. reported its Q3 2024 financial results, showing a decrease in revenue and a net loss, while continuing its strategic review process.

Summary

• Venus Concept Inc. reported a net loss of $9.3 million for the third quarter of 2024, compared to a net loss of $9.0 million in the same period of 2023.
• The company's revenue decreased to $15.0 million in Q3 2024 from $17.6 million in Q3 2023, primarily due to tighter credit markets and a strategic exit from unprofitable direct markets.
• The company's gross profit decreased to $9.9 million in Q3 2024 from $12.2 million in Q3 2023.
• Operating expenses decreased to $17.1 million in Q3 2024 from $18.9 million in Q3 2023.
• The company's cash and cash equivalents were $4.5 million as of September 30, 2024, compared to $5.4 million as of December 31, 2023.
• The company is undergoing a strategic review to maximize shareholder value, which may include financings, mergers, or asset sales.
• The company has an accumulated deficit of $300.9 million as of September 30, 2024.
• The company's recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with declining revenue, net losses, and a going concern warning. While there are some positive aspects like reduced cash burn, the overall sentiment is negative due to the company's financial instability and uncertain future.

Positives

• Cash used in operations was 40% lower in the first nine months of 2024 compared to the same period in 2023.
• The company is actively managing its supply chain and has not experienced significant disruptions.
• The company is focused on improving cash generation by prioritizing cash sales over internal financing programs.
• The company's allowance for expected credit losses decreased by 43% from December 31, 2023 to September 30, 2024.

Negatives

• The company's revenue decreased by 14.8% year-over-year in Q3 2024.
• The company reported a net loss of $9.3 million in Q3 2024.
• Gross margin decreased to 66.1% in Q3 2024 from 69.2% in Q3 2023.
• The company has an accumulated deficit of $300.9 million as of September 30, 2024.
• The company's recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern.

Risks

• The company's dependency on internal lease programs exposes it to customer credit risk.
• Customers' ability to secure third-party financing is impacted by tightened credit markets and higher interest rates.
• The company's operations are subject to extensive governmental regulation and oversight.
• The company's operations in Israel may be adversely affected by political, economic, and military conditions.
• The company's ability to remain in compliance with Nasdaq listing requirements is uncertain.
• The company is dependent on one major contract manufacturer in Israel, which exposes it to supply disruptions.
• The company's ability to access capital markets and obtain credit on favorable terms is uncertain.
• The company is exposed to inflation, currency fluctuations, and global supply disruptions.
• The company is exposed to global economic and political conditions and uncertainties, including the Russia-Ukraine and Israel-Hamas conflicts.

Future Outlook

The company expects to continue to incur substantial operating losses and negative cash flows until it generates sufficient revenue to support its cost structure. The company plans to fund its operations with cash on hand, borrowings, and issuances of capital stock. The company is also focused on adapting to the challenges presented by the current macro-economic environment, as well as the opportunities presented by an easing of monetary policy.

Management Comments

• The company is undergoing a strategic review to maximize shareholder value.
• The company is focused on improving cash generation by prioritizing cash sales over internal financing programs.
• The company is actively managing its supply chain and has not experienced significant disruptions, but is facing inflationary pressures.

Industry Context

The medical aesthetics industry is competitive, and Venus Concept faces challenges from both established players and new entrants. The company's strategic review and focus on cash generation reflect a broader trend in the industry towards financial sustainability and profitability. The company's focus on robotic technology and AI.ME platform is an attempt to differentiate itself in the market.

Comparison to Industry Standards

• The company's revenue decline and net losses are concerning when compared to industry leaders in the medical aesthetics space, such as Allergan (now part of AbbVie) and Merz, which typically report consistent revenue growth and profitability.
• The company's gross margin of 66.1% is lower than the industry average for medical device companies, which often exceeds 70%.
• The company's high operating expenses as a percentage of revenue (113.8%) indicate a need for greater cost control and efficiency compared to industry benchmarks.
• The company's reliance on internal financing programs, while providing flexibility to customers, also exposes it to higher credit risk compared to companies that primarily sell through distributors or third-party financing.
• The company's cash burn rate, while improved, remains a concern compared to more established and profitable companies in the industry.

Related Party Transactions

• The company had distribution agreements with Technicalbiomed Co., Ltd. (TBC) and Aexel Biomed Pte Ltd. (Aexel Biomed), both of which ceased being related parties as of June 2023.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting from Nasdaq.
• Employees may be affected by potential restructuring or cost-cutting measures.
• Customers may experience changes in service or product availability due to the company's financial challenges.
• Suppliers may face increased risk of payment delays or defaults.
• Creditors face increased risk of non-payment or default on debt obligations.

Next Steps

• The company will continue to evaluate strategic alternatives to maximize shareholder value.
• The company will focus on improving cash generation by prioritizing cash sales.
• The company will continue to manage its supply chain and mitigate inflationary pressures.
• The company will work to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

medical aesthetics, hair restoration, minimally invasive, non-invasive, Venus Concept, financial results, strategic review, credit risk, supply chain, Nasdaq, debt financing, operating losses